Navigation Links
Atlas Appoints David Whitaker as Operations Director
Date:11/27/2013

BATH, England, November 27, 2013 /PRNewswire/ --

Atlas Genetics Ltd ("Atlas" or the "Company"), a diagnostic company developing ultra-rapid point-of-care tests for a range of infectious diseases, today announces the appointment of David Whitaker as Operations Director with immediate effect.

David joins Atlas from DNA Electronics, where he worked as Manufacturing & Mechanical Engineering Manager, responsible for the development of a fully portable, point-of-care genetic test device.  This project involved a wide range of technical disciplines including microfluidics, electronics and molecular biology.  He worked closely with the acting Chief Scientific Officer on the overall management of the project and held direct responsibility for all device engineering activities.  

Prior to this, he spent five years as a Principal Consultant in PA Consulting's Technology and Innovation Practice.  During his tenure, he successfully developed and patented a range of medical devices for both big pharma and start-up companies.  Before joining PA Consulting, David worked in a variety of medical device engineering, contract engineering and consulting positions at companies including Ivax Pharmaceuticals, Futura Medical West Pharmaceuticals and Risdon Pharma.

David has First Class BEng degree in Mechanical & Manufacturing Engineering with Management from the University of Leeds.

Dr John Clarkson, Chief Executive Officer of Atlas, commented: "At Atlas, we have worked hard over the past year to enhance and develop our senior management team.  David brings considerable operational expertise which will be important as we enter a new phase of product manufacture and growth, further progressing Atlas towards becoming a first class diagnostics company."

About Atlas (http://www.atlasgenetics.com)

Atlas (Atlas Genetics Ltd) develops ultra-rapid point-of-care (POC) diagnostic tests for infectious diseases.  The Atlas io™ system uses patented technology based on the use of a novel electrochemical sensor that combines speed, accuracy and multiplex detection capability.  The Company has its head office and laboratory facilities near Bath.  Atlas was established in 2005 and is financed by VC, corporate and private investors including Consort Medical plc, Novartis Venture Funds, J&J Development Corporation, Life Science Partners (LSP), BB Biotech Ventures and YFM Equity Partners.  The company raised £16.9 million in series B finance in 2011.

The Atlas io™ platform

POC diagnostics offer health professionals the ability to test for medical conditions at the site of patient care.  Atlas has developed the io™ system, a flexible POC technology platform, which has been designed to accurately and quickly diagnose a wide range of medical conditions within 30 minutes.  The Atlas io™ system consists of an inexpensive test machine into which a disposable cartridge containing a patient sample is inserted.  The io™ platform is scheduled for clinical trials in 2014, followed by rollout in Europe and the United States, pending regulatory approvals.

Atlas is developing tests for a range of infectious diseases including sexually transmitted infections and hospital acquired infections.  The io™ system will initially be launched for the rapid testing of Chlamydia, allowing clinicians to test and treat patients in a single visit.  Around 40 million tests are carried out for these diseases in Europe and the US every year.  According to the European Centre for Disease Prevention and Control, Chlamydia is the most frequently reported bacterial Sexually Transmitted Infection (STI), with prevalence rates in young people between 5-10%, whilst Gonorrhoea is the second most commonly 'reported' STI.  An increasing awareness, number of reported cases and increased testing for Gonorrhoea, Trichomonasvaginalis and Mycoplasma genitalium infection means these are a logical extension to the STI test menu for the io™ platform.  The worldwide in vitro diagnostic market for infectious disease testing is estimated to be worth around US$9 billion.

Contact details:

Atlas Genetics Ltd:    
John Clarkson    
Tel: +44(0)1225-717930
   
FTI Consulting:    
Mo Noonan / Ben Atwell    
Tel: +44(0)207-831-3113



'/>"/>
SOURCE Atlas Genetics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Roka Bioscience Atlas System For Food Pathogen Detection Integrated At Department of Defense Food Analysis and Diagnostic Laboratory
2. Proteome atlas for the tuberculosis pathogen
3. Quadrant Engineering Plastic Products Assigns Production of Acetron® GP and Nylon 101 Hex/Square Rods to Atlas Fibre Company
4. Cancer Antibodies: Drug Target Atlas and Competitive Outlook
5. Roka Bioscience Kicks Off Atlas on Tour, a Mobile Demonstration Vehicle for the Food Safety Industry, at IAFP
6. CMDBioscience Appoints Tomi Sawyer to Scientific Advisory Board; Entrepreneurial Drug Hunter and Distinguished Scholar Named as Founding Chair
7. Boston Biomedical Appoints Patricia S. Andrews as Chief Commercial Officer
8. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
9. Convoy Therapeutics Appoints Clinical Advisory Board
10. Egenix, Inc. Appoints Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee
11. Metamark Appoints Cornelius J. Merlini Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... 03, 2016 , ... Leading CEOs from biotech, pharmaceutical, and ... June 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/3/2016)... LONDON , May 3, 2016 ... Report Assessing Developers and Producers of Those Competitor Biologics  ... Guide to Companies, Activities and Prospects ,  ... drug companies? And what are their sales potentials? ... There you see results, trends, opportunities and revenue forecasting. ...
(Date:5/2/2016)... YORK , May 2, 2016 ... announces that its technology partner Mannin Research Inc. will ... Ophthalmology (ARVO), which takes place from May 1-5, 2016 ... executives will be meeting with its vendors and research ... explore business development goals and other collaborative opportunities for ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design team has won ... explored how bacterial properties can be applied to fabric and formed into living interfaces ... in response to humidity change. The team harvested Natto cells and applied them to ...
Breaking Biology Technology:
(Date:3/15/2016)... , March 15, 2016 --> ... published by Transparency Market Research "Digital Door Lock Systems Market ... 2015 - 2023," the global digital door lock systems market ... in 2014 and is forecast to grow at a CAGR ... micro, small and medium enterprises (MSMEs) across the world and ...
(Date:3/11/2016)... 2016 http://www.apimages.com ) - --> ... available at AP Images ( http://www.apimages.com ) - ... to produce the new refugee identity cards. DERMALOG will be unveiling ... in Hanover next week.   --> ... used to produce the new refugee identity cards. DERMALOG will be ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
Breaking Biology News(10 mins):